PSY12 A Budget Impact Analysis of Tapentadol Extended Release (ER) for the Treatment of Moderate to Severe Chronic Pain

Tapentadol ER is a new oral analgesic that has been shown to have a lower incidence of gastrointestinal adverse events (AEs) than oxycodone CR at equianalgesic doses. We estimated the annual budget impact of placing tapentadol ER on a health plan formulary of long-acting opioids (LAOs) used to treat moderate to severe chronic pain. An Excel-based budget impact model was developed to estimate the annual direct healthcare costs associated with...